Theriva Biologics, Inc. SEC filings TOVX
Theriva Biologics, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Jun 25, 1998. Its latest annual report, Form ARS, was filed on Jun 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (material agreement, acquisition or sale of assets, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Dec 2, 2025 | — |
| CORRESP | Letter to the SEC | Dec 1, 2025 | — |
| D | Filing | Oct 24, 2025 | — |
| EFFECT | Filing | May 7, 2025 | — |
| CORRESP | Letter to the SEC | May 5, 2025 | — |
| CORRESP | Letter to the SEC | May 5, 2025 | — |
| CORRESP | Letter to the SEC | Jan 23, 2025 | — |
| CORRESP | Letter to the SEC | Jan 23, 2025 | — |
| CORRESP | Letter to the SEC | Jan 21, 2025 | — |
| CORRESP | Letter to the SEC | Jan 21, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 16, 2024 | — |
| EFFECT | Filing | Sep 25, 2024 | — |
| EFFECT | Filing | Sep 25, 2024 | — |
| CORRESP | Letter to the SEC | Sep 23, 2024 | — |
| CORRESP | Letter to the SEC | Sep 20, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 16, 2024 | — |
| UPLOAD | Letter from the SEC | May 8, 2024 | — |
| DEFR14A | Filing | Aug 16, 2023 | — |
| EFFECT | Filing | Dec 8, 2022 | — |
| EFFECT | Filing | Sep 14, 2022 | — |
| CORRESP | Letter to the SEC | Sep 12, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 9, 2022 | — |
| D | Filing | Aug 4, 2022 | — |
| D | Filing | Mar 21, 2022 | — |
| EFFECT | Filing | Nov 2, 2021 | — |
| CORRESP | Letter to the SEC | Oct 29, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 29, 2021 | — |
| DEFR14A | Filing | Aug 25, 2021 | — |
| DEFR14A | Filing | Aug 17, 2021 | — |
| EFFECT | Filing | May 11, 2021 | — |
| CORRESP | Letter to the SEC | May 7, 2021 | — |
| UPLOAD | Letter from the SEC | May 7, 2021 | — |
| EFFECT | Filing | Oct 10, 2018 | — |
| CORRESP | Letter to the SEC | Oct 4, 2018 | — |
| CORRESP | Letter to the SEC | Oct 4, 2018 | — |
| UPLOAD | Letter from the SEC | Sep 25, 2018 | — |
| EFFECT | Filing | Aug 22, 2018 | — |
| CORRESP | Letter to the SEC | Aug 20, 2018 | — |
| CORRESP | Letter to the SEC | Aug 16, 2018 | — |
| UPLOAD | Letter from the SEC | Aug 15, 2018 | — |
| EFFECT | Filing | May 15, 2018 | — |
| UPLOAD | Letter from the SEC | May 15, 2018 | — |
| CORRESP | Letter to the SEC | May 14, 2018 | — |
| UPLOAD | Letter from the SEC | Sep 20, 2017 | — |
| D | Filing | Sep 13, 2017 | — |
| CORRESP | Letter to the SEC | Aug 24, 2017 | — |
| UPLOAD | Letter from the SEC | Aug 18, 2017 | — |
| EFFECT | Filing | Oct 15, 2015 | — |
| CORRESP | Letter to the SEC | Oct 14, 2015 | — |
| UPLOAD | Letter from the SEC | Oct 14, 2015 | — |
| CT ORDER | Filing | Aug 24, 2015 | — |
| EFFECT | Filing | Aug 18, 2015 | — |
| EFFECT | Filing | Aug 18, 2015 | — |
| CORRESP | Letter to the SEC | Aug 14, 2015 | — |
| CORRESP | Letter to the SEC | Aug 14, 2015 | — |
| UPLOAD | Letter from the SEC | Aug 14, 2015 | — |
| UPLOAD | Letter from the SEC | Aug 14, 2015 | — |
| EFFECT | Filing | Apr 20, 2015 | — |
| EFFECT | Filing | Apr 20, 2015 | — |
| CT ORDER | Filing | Dec 31, 2013 | — |
| EFFECT | Filing | Jul 16, 2013 | — |
| EFFECT | Filing | May 6, 2013 | — |
| NT 10-K | Filing | Apr 2, 2013 | Dec 31, 2012 |
| CT ORDER | Filing | Jan 18, 2013 | — |
| EFFECT | Filing | Dec 20, 2012 | — |
| CT ORDER | Filing | Dec 10, 2012 | — |
| D | Filing | Nov 5, 2012 | — |
| D | Filing | Oct 22, 2012 | — |
| CT ORDER | Filing | Aug 29, 2012 | — |
| POS EX | Post-effective amendment | Aug 10, 2012 | — |
| EFFECT | Filing | Jul 23, 2012 | — |
| UPLOAD | Letter from the SEC | May 31, 2012 | — |
| CORRESP | Letter to the SEC | May 30, 2012 | — |
| UPLOAD | Letter from the SEC | May 22, 2012 | — |
| EFFECT | Filing | Apr 13, 2012 | — |
| CT ORDER | Filing | Feb 17, 2012 | — |
| UPLOAD | Letter from the SEC | Mar 1, 2011 | — |
| CORRESP | Letter to the SEC | Feb 8, 2011 | — |
| UPLOAD | Letter from the SEC | Jan 31, 2011 | — |
| CORRESP | Letter to the SEC | Dec 22, 2010 | — |
| CORRESP | Letter to the SEC | Dec 22, 2010 | — |
| UPLOAD | Letter from the SEC | Dec 15, 2010 | — |
| EFFECT | Filing | Jun 14, 2010 | — |
| CORRESP | Letter to the SEC | Jun 10, 2010 | — |
| CT ORDER | Filing | Jun 9, 2010 | — |
| UPLOAD | Letter from the SEC | May 21, 2010 | — |
| PRER14A | Preliminary 14a | Nov 19, 2009 | — |
| EFFECT | Filing | Feb 6, 2009 | — |
| AW | Form aw | Nov 13, 2008 | — |
| UPLOAD | Letter from the SEC | Oct 22, 2008 | — |
| 10KSB/A | Form 10-ksb/a | Aug 29, 2008 | Dec 31, 2007 |
| UPLOAD | Letter from the SEC | Aug 26, 2008 | — |
| UPLOAD | Letter from the SEC | May 7, 2008 | — |
| CORRESP | Letter to the SEC | Apr 29, 2008 | — |
| CORRESP | Letter to the SEC | Apr 28, 2008 | — |
| UPLOAD | Letter from the SEC | Apr 25, 2008 | — |
| 10QSB | Form 10-qsb | Nov 14, 2007 | Sep 30, 2007 |
| 10QSB | Filing | Aug 14, 2007 | Mar 30, 2007 |
| CERTAMX | Auto-generated paper document | Jun 26, 2007 | — |
| 8-A12B | Filing | Jun 20, 2007 | — |
| 10QSB | Filing | May 14, 2007 | Mar 31, 2007 |
| 10KSB | Filing | Apr 2, 2007 | Dec 31, 2006 |
| EFFECT | Filing | Feb 13, 2007 | — |
| CORRESP | Letter to the SEC | Feb 9, 2007 | — |
| SB-2/A | Form sb-2/a | Feb 9, 2007 | — |
| CORRESP | Letter to the SEC | Jan 25, 2007 | — |
| UPLOAD | Letter from the SEC | Jan 24, 2007 | — |
| UPLOAD | Letter from the SEC | Jan 24, 2007 | — |
| CORRESP | Letter to the SEC | Jan 5, 2007 | — |
| SB-2 | Filing | Dec 14, 2006 | — |
| 10QSB | Quarterly report for the period ended september 30, 2006 | Oct 12, 2006 | Sep 30, 2006 |
| 10QSB | Quarterly report for the period ended june 30, 2006 | Aug 2, 2006 | Jun 30, 2006 |
| 10QSB | Quarterly report for the period ended march 31, 2006 | May 12, 2006 | Mar 31, 2006 |
| 10KSB | Form 10-ksb for the year ended december 31 2005 | Jan 25, 2006 | Dec 31, 2005 |
| 10QSB | Form 10-qsb for the period ended september 30, 2005 | Nov 14, 2005 | Sep 30, 2005 |
| 10QSB | Form 10-qsb for the period ended june 30, 2005 | Aug 4, 2005 | Jun 30, 2005 |
| 10QSB | Form 10-qsb for the period ended march 31, 2005 | Jul 19, 2005 | Mar 31, 2005 |
| 10KSB | Form 10-ksb for the year ended december 31, 2004 | Jul 19, 2005 | Dec 31, 2004 |
| 10QSB | Form 10-qsb for the period ended september 30, 2004 | Jul 19, 2005 | Sep 30, 2004 |
| 10QSB | Form 10-qsb for the period ended june 30, 2004 | Jul 19, 2005 | Jun 30, 2004 |
| 10QSB | Form 10-qsb for the period ended march 31, 2004 | Jul 15, 2005 | Mar 31, 2004 |
| 10KSB | Form 10-ksb for the year ended december 31, 2003 | Jul 15, 2005 | Dec 31, 2003 |
| 10QSB | Form 10-qsb for the period ended september 30, 2003 | Jul 15, 2005 | Sep 30, 2003 |
| 10QSB | Form 10-qsb for the period ended june 30, 2003 | Jul 15, 2005 | Jun 30, 2003 |
| NT 10-K | Notification of late filing | Mar 28, 2003 | Dec 31, 2002 |
| 10-K405 | Annual report | Mar 29, 2002 | Dec 31, 2001 |
| 10-K405 | Form 10-k | Mar 13, 2001 | Dec 31, 2000 |
Showing 127 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TOVX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Rockville, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 894158
- Former names
- Synthetic Biologics, Inc. (until Oct 12, 2022); ADEONA PHARMACEUTICALS, INC. (until Feb 17, 2012); PIPEX PHARMACEUTICALS, INC. (until Oct 16, 2008); SHEFFIELD PHARMACEUTICALS INC (until Dec 8, 2006); SHEFFIELD MEDICAL TECHNOLOGIES INC (until May 14, 1997)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.